imlunestrant

30 December, 2024

A new drug improves clinical outcomes for patients with advanced breast cancer

A Phase 3 clinical trial demonstrates that the combination of imlunestrant and abemaciclib improves progression-free survival in advanced ER+ HER2- breast cancer, regardless of genomic profile. The compound as monotherapy only shows benefits in patients with mutations in the ESR1 gene.